Maziers N, Bulpa P, Jamart J, Delaunois L, Eucher Ph, Evrard P
Lung Transplant and Biostatistics Units, Centre Hospitalier Universitaire Mont-Godinne, Université Catholique de Louvain, Yvoir, Belgium.
Transplant Proc. 2012 Nov;44(9):2880-4. doi: 10.1016/j.transproceed.2012.09.081.
Although the reliability of cyclosporine (CyA) concentration at 2 (C2) hours postdosing has been established for kidney, liver, and heart transplant recipients, its use in lung cases remains to be validated. We investigated the relationship between CyA dual time point monitoring and long-term functional outcomes after lung transplantation.
We included data from 38 lung transplant recipients receiving CyA, azathioprins, and steroids in the study. CyA dosages were based on the trough concentrations. CyA concentrations at 0 (C0) and 2 (C2) hours postdosing were obtained at 1, 2, 3, 6, 9, 12, 15, 18, and 24 months postoperative. We retrospectively compared average CyA level (C0 and C2) during the first 3 posttransplantation months with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), forced expiratory flow 25%-75 % (FEF 25-75), creatinine, systolic blood pressure (SBP), and diastolic blood pressure (DBP) using regression analysis via generalized estimating equations (GEE).
Only improvement in FVC (P = .033) and deterioration of SBP (P < .001) were related to C0 monitoring. No correlation was observed between C0 and FEV1 (P = .13), FEF 25-75 (P = .48), creatinine (P = .07), and DBP (P = .97). Nor was any relationship observed between C2 concentrations and FEV1 (P = .64), FVC (P = .38), FEF 25-75 (P = .09), creatinine (P = .95), SBP (P = .73), or DBP (P = .51).
There was a lack of a relationship between CyA concentrations (C0 and C2) and functional outcomes among de novo lung transplantations except for a positive correlation of 0 value with long-term improved FVC and increased SBP. This study suggested that C2 determinations may not improving lung recipient management.
尽管肾、肝和心脏移植受者给药后2小时(C2)的环孢素(CyA)浓度可靠性已得到证实,但其在肺移植病例中的应用仍有待验证。我们研究了肺移植后CyA双时间点监测与长期功能结局之间的关系。
我们纳入了38例接受CyA、硫唑嘌呤和类固醇治疗的肺移植受者的数据。CyA剂量基于谷浓度。在术后1、2、3、6、9、12、15、18和24个月获取给药后0(C0)和2(C2)小时的CyA浓度。我们通过广义估计方程(GEE)进行回归分析,回顾性比较移植后前3个月的平均CyA水平(C0和C2)与第1秒用力呼气量(FEV1)、用力肺活量(FVC)、25%-75%用力呼气流量(FEF 25-75)、肌酐水平、收缩压(SBP)和舒张压(DBP)之间的关系。
仅FVC的改善(P = 0.033)和SBP的恶化(P < 0.001)与C0监测相关。未观察到C0与FEV1(P = 0.13)、FEF 25-75(P = 0.48)、肌酐(P = 0.07)和DBP(P = 0.97)之间存在相关性。也未观察到C2浓度与FEV1(P = 0.64)、FVC(P = 0.38)、FEF 25-75(P = 0.09)、肌酐(P = 0.95)、SBP(P = 0.73)或DBP(P = 0.51)之间存在任何关系。
除0值与长期改善的FVC和升高的SBP呈正相关外,在初次肺移植中,CyA浓度(C0和C2)与功能结局之间缺乏相关性。本研究表明,C2测定可能无法改善肺移植受者的管理。